Attached files

file filename
S-1 - FORM S-1 - Nexvet Biopharma plcd775834ds1.htm
EX-10.18 - EX-10.18 - Nexvet Biopharma plcd775834dex1018.htm
EX-4.2 - EX-4.2 - Nexvet Biopharma plcd775834dex42.htm
EX-10.12 - EX-10.12 - Nexvet Biopharma plcd775834dex1012.htm
EX-10.4 - EX-10.4 - Nexvet Biopharma plcd775834dex104.htm
EX-99.1 - EX-99.1 - Nexvet Biopharma plcd775834dex991.htm
EX-10.16 - EX-10.16 - Nexvet Biopharma plcd775834dex1016.htm
EX-10.13 - EX-10.13 - Nexvet Biopharma plcd775834dex1013.htm
EX-10.7 - EX-10.7 - Nexvet Biopharma plcd775834dex107.htm
EX-4.3 - EX-4.3 - Nexvet Biopharma plcd775834dex43.htm
EX-21.1 - EX-21.1 - Nexvet Biopharma plcd775834dex211.htm
EX-10.11 - EX-10.11 - Nexvet Biopharma plcd775834dex1011.htm
EX-10.8 - EX-10.8 - Nexvet Biopharma plcd775834dex108.htm
EX-3.2 - EX-3.2 - Nexvet Biopharma plcd775834dex32.htm
EX-10.9 - EX-10.9 - Nexvet Biopharma plcd775834dex109.htm
EX-10.14 - EX-10.14 - Nexvet Biopharma plcd775834dex1014.htm
EX-10.5 - EX-10.5 - Nexvet Biopharma plcd775834dex105.htm
EX-10.15 - EX-10.15 - Nexvet Biopharma plcd775834dex1015.htm
EX-10.19 - EX-10.19 - Nexvet Biopharma plcd775834dex1019.htm
EX-10.2 - EX-10.2 - Nexvet Biopharma plcd775834dex102.htm
EX-10.10 - EX-10.10 - Nexvet Biopharma plcd775834dex1010.htm
EX-10.6 - EX-10.6 - Nexvet Biopharma plcd775834dex106.htm
EX-10.1 - EX-10.1 - Nexvet Biopharma plcd775834dex101.htm
EX-3.1 - EX-3.1 - Nexvet Biopharma plcd775834dex31.htm
EX-23.2 - EX-23.2 - Nexvet Biopharma plcd775834dex232.htm
EX-10.3 - EX-10.3 - Nexvet Biopharma plcd775834dex103.htm
EX-10.17 - EX-10.17 - Nexvet Biopharma plcd775834dex1017.htm

Exhibit 16.1

September 5, 2014

Securities and Exchange Commission

100 F Street, N.E.

Washington, DC 20549

Ladies and Gentlemen:

We have read the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Change in Principal Auditor” in the Registration Statement Form S-1, confidentially submitted on September 5, 2014, of Nexvet Biopharma plc and are in agreement with the statements contained in the first and second paragraphs therein. We have no basis to agree or disagree with other statements contained therein.

Regarding the statement concerning the lack of internal control to prepare financial statements included in the second paragraph under the section titled “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Change in Principal Auditor,” we had considered such matter in determining the nature, timing and extent of procedures performed in our audits of Nexvet Biopharma Pty Ltd’s 2012 and 2013 financial statements which were audited in accordance with generally accepted auditing standards in Australia and prepared in accordance with international financial reporting standards generally accepted in Australia.

Sincerely,

/s/ Ernst & Young

Melbourne, Victoria

Australia